Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; and Huyabio. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Overall MarketRank^™

2.34 out of 5 stars

Medical Sector

14th out of 2,041 stocks

Pharmaceutical Preparations Industry

6th out of 769 stocks

2.4 Analyst's Opinion

Consensus Rating
Bristol-Myers Squibb has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $74.33, Bristol-Myers Squibb has a forecasted upside of 15.4% from its current price of $64.40.
Amount of Analyst Coverage
Bristol-Myers Squibb has only been the subject of 4 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Bristol-Myers Squibb has received 1,035 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Bristol-Myers Squibb has received 930 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Bristol-Myers Squibb has received 52.67% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote “Outperform” if you believe BMY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Yield
Bristol-Myers Squibb pays a meaningful dividend of 3.03%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Bristol-Myers Squibb has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Bristol-Myers Squibb is 41.79%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Bristol-Myers Squibb will have a dividend payout ratio of 26.78% next year. This indicates that Bristol-Myers Squibb will be able to sustain or increase its dividend.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bristol-Myers Squibb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,555,000.00 in company stock.
Percentage Held by Insiders
Only 0.14% of the stock of Bristol-Myers Squibb is held by insiders.
Percentage Held by Institutions
72.41% of the stock of Bristol-Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5 Earnings and Valuation

Earnings Growth
Earnings for Bristol-Myers Squibb are expected to grow by 15.28% in the coming year, from $6.35 to $7.32 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bristol-Myers Squibb is -585.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bristol-Myers Squibb is -585.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Bristol-Myers Squibb has a PEG Ratio of 1.00. PEG Ratios around 1 indicate that a company is correctly valued.
Price to Book Value per Share Ratio
Bristol-Myers Squibb has a P/B Ratio of 2.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

Is Bristol-Myers Squibb a buy right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last twelve months. There are currently 3 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Bristol-Myers Squibb stock.
View analyst ratings for Bristol-Myers Squibb or view top-rated stocks.

What stocks does MarketBeat like better than Bristol-Myers Squibb?

Wall Street analysts have given Bristol-Myers Squibb a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bristol-Myers Squibb wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Bristol-Myers Squibb?

Bristol-Myers Squibb saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 16,860,000 shares, a decline of 33.0% from the March 15th total of 25,160,000 shares. Based on an average daily volume of 12,620,000 shares, the short-interest ratio is presently 1.3 days.
View Bristol-Myers Squibb's Short Interest.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Bristol-Myers Squibb.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb (NYSE:BMY) posted its earnings results on Wednesday, April, 28th. The biopharmaceutical company reported $1.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.82 by $0.08. The biopharmaceutical company had revenue of $11.07 billion for the quarter, compared to the consensus estimate of $11.19 billion. Bristol-Myers Squibb had a positive trailing twelve-month return on equity of 27.48% and a negative net margin of 0.11%. The business's quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.72 earnings per share.
View Bristol-Myers Squibb's earnings history.

How has Bristol-Myers Squibb's stock price been impacted by Coronavirus?

Bristol-Myers Squibb's stock was trading at $108.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BMY shares have decreased by 40.6% and is now trading at $64.28.
View which stocks have been most impacted by COVID-19.

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb declared a quarterly dividend on Monday, March 1st. Investors of record on Thursday, April 1st will be paid a dividend of $0.49 per share on Monday, May 3rd. This represents a $1.96 annualized dividend and a yield of 3.05%. The ex-dividend date of this dividend is Wednesday, March 31st.
View Bristol-Myers Squibb's dividend history.

Is Bristol-Myers Squibb a good dividend stock?

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and currently has a dividend yield of 3.03%. Bristol-Myers Squibb does not yet have a strock track record of dividend growth. The dividend payout ratio of Bristol-Myers Squibb is 41.79%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bristol-Myers Squibb will have a dividend payout ratio of 26.78% next year. This indicates that Bristol-Myers Squibb will be able to sustain or increase its dividend.
View Bristol-Myers Squibb's dividend history.

When did Bristol-Myers Squibb's stock split? How did Bristol-Myers Squibb's stock split work?

Bristol-Myers Squibb's stock split before market open on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly issued shares were distributed to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Bristol-Myers Squibb stock prior to the split would have 200 shares after the split.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb updated its FY 2021 earnings guidance on Thursday, May, 6th. The company provided EPS guidance of 7.350-7.550 for the period, compared to the Thomson Reuters consensus estimate of $7.480. The company issued revenue guidance of -.

What price target have analysts set for BMY?

16 brokerages have issued 12 month price targets for Bristol-Myers Squibb's shares. Their forecasts range from $62.00 to $88.00. On average, they expect Bristol-Myers Squibb's share price to reach $74.33 in the next year. This suggests a possible upside of 15.6% from the stock's current price.
View analysts' price targets for Bristol-Myers Squibb or view top-rated stocks among Wall Street analysts.

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the following people:

Dr. Giovanni Caforio, Chairman & CEO (Age 56, Pay $6.22M) (LinkedIn Profile)
Mr. David V. Elkins, Exec. VP & CFO (Age 53, Pay $3.62M) (LinkedIn Profile)
Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 60, Pay $2.92M) (LinkedIn Profile)
Dr. Christopher S. Boerner, Exec. VP & Chief Commercialization Officer (Age 50, Pay $2.49M) (LinkedIn Profile)
Mr. Rupert Vessey M.A., Exec. VP and Pres of Research & Early Devel. (Age 56, Pay $3.31M) (LinkedIn Profile)
Mr. Paul von Autenried, Exec. VP & Chief Information Officer (Age 59) (LinkedIn Profile)
Mr. Timothy Power, VP & Head of Investor Relations
Mr. Adam Dubow, Sr. VP, Chief Compliance & Ethics Officer (Age 54) (LinkedIn Profile)
Ms. Ann M. Powell Judge, Exec. VP & Chief HR Officer (Age 55) (LinkedIn Profile)
Mr. Louis S. Schmukler, Exec. VP and Pres of Global Product Devel. & Supply (Age 65) (LinkedIn Profile)

What is Giovanni Caforio's approval rating as Bristol-Myers Squibb's CEO?

659 employees have rated Bristol-Myers Squibb CEO Giovanni Caforio on Glassdoor.com. Giovanni Caforio has an approval rating of 89% among Bristol-Myers Squibb's employees.

Who are some of Bristol-Myers Squibb's key competitors?

Some companies that are related to Bristol-Myers Squibb include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Eli Lilly and (LLY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of BMY's competitors.

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), NVIDIA (NVDA), CVS Health (CVS), Cisco Systems (CSCO) and Bank of America (BAC).

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by a variety of institutional and retail investors. Top institutional investors include LSV Asset Management (0.47%), Swiss National Bank (0.39%), Sumitomo Mitsui Trust Holdings Inc. (0.39%), The PNC Financial Services Group Inc. (0.31%), Standard Life Aberdeen plc (0.24%) and Alliancebernstein L.P. (0.22%). Company insiders that own Bristol-Myers Squibb stock include Adam Dubow, Autenried Paul Von, Dinesh C Paliwal, Giovanni Caforio, John E Elicker, Joseph Eid, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini, Rupert Vessey, Sandra Leung, Terrie Curran and Theodore R Samuels II.
View institutional ownership trends for Bristol-Myers Squibb.

Which major investors are selling Bristol-Myers Squibb stock?

BMY stock was sold by a variety of institutional investors in the last quarter, including Bank of Nova Scotia, Institute for Wealth Management LLC., The Manufacturers Life Insurance Company , LSV Asset Management, State of New Jersey Common Pension Fund D, Douglas Lane & Associates LLC, PGGM Investments, and Exencial Wealth Advisors LLC. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Adam Dubow, Autenried Paul Von, Giovanni Caforio, Joseph Eid, Louis S Schmukler, Rupert Vessey, and Sandra Leung.
View insider buying and selling activity for Bristol-Myers Squibb or view top insider-selling stocks.

Which major investors are buying Bristol-Myers Squibb stock?

BMY stock was purchased by a variety of institutional investors in the last quarter, including State of Michigan Retirement System, GSB Wealth Management LLC, Oak Ridge Investments LLC, Standard Life Aberdeen plc, Robeco Institutional Asset Management B.V., Alliancebernstein L.P., Polaris Wealth Advisory Group LLC, and Wesbanco Bank Inc.. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Robert J Bertolini, and Theodore R Samuels II.
View insider buying and selling activity for Bristol-Myers Squibb or or view top insider-buying stocks.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $64.28.

How much money does Bristol-Myers Squibb make?

Bristol-Myers Squibb has a market capitalization of $143.53 billion and generates $26.15 billion in revenue each year. The biopharmaceutical company earns $3.44 billion in net income (profit) each year or $4.69 on an earnings per share basis.

How many employees does Bristol-Myers Squibb have?

Bristol-Myers Squibb employs 30,250 workers across the globe.

Does Bristol-Myers Squibb have any subsidiaries?

The following companies are subsidiares of Bristol-Myers Squibb: 1096271 B.C. ULC, 345 Park LLC, A.G. Medical Services P.A., AHI Investment LLC, AbVitro LLC, Abraxis BioScience Australia Pty Ltd., Abraxis BioScience Inc., Abraxis BioScience International Holding Company Inc., Abraxis BioScience LLC, Abraxis BioScience Puerto Rico LLC, Acetylon Pharmaceuticals Inc., Adnexus, Adnexus a Bristol-Myers Squibb R&D Company, Allard Labs Acquisition G.P., Amira Pharmaceuticals, Amira Pharmaceuticals Inc., Amylin Pharmaceuticals, Apothecon LLC, B-MS Generx Unlimited Company, BMS Benelux Holdings B.V., BMS Bermuda Nominees L.L.C., BMS Data Acquisition Company LLC, BMS Forex Company, BMS Holdings Sarl, BMS Holdings Spain S.L., BMS International Insurance Designated Activity Company, BMS Investco SAS, BMS Korea Holdings L.L.C., BMS Latin American Nominees L.L.C., BMS Luxembourg Partners L.L.C., BMS Omega Bermuda Holdings Finance Ltd., BMS Pharmaceutical Korea Limited, BMS Pharmaceuticals Germany Holdings B.V., BMS Pharmaceuticals International Holdings Netherlands B.V., BMS Pharmaceuticals Korea Holdings B.V., BMS Pharmaceuticals Mexico Holdings B.V., BMS Pharmaceuticals Netherlands Holdings B.V., BMS Real Estate LLC, BMS Spain Investments LLC, BMS Strategic Portfolio Investments Holdings Inc., Blisa Acquisition G.P., Bristol (Iran) S.A., Bristol Iran Private Company Limited, Bristol Laboratories Inc., Bristol Laboratories International S.A., Bristol Laboratories Medical Information Systems Inc., Bristol-Myers (Andes) L.L.C., Bristol-Myers (Private) Limited, Bristol-Myers Middle East S.A.L., Bristol-Myers Overseas Corporation, Bristol-Myers Squibb (China) Investment Co. Ltd., Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd., Bristol-Myers Squibb (Israel) Ltd., Bristol-Myers Squibb (NZ) Limited, Bristol-Myers Squibb (Proprietary) Limited, Bristol-Myers Squibb (Shanghai) Trading Co. Ltd., Bristol-Myers Squibb (Singapore) Pte. Limited, Bristol-Myers Squibb (Taiwan) Ltd., Bristol-Myers Squibb (West Indies) Ltd., Bristol-Myers Squibb A.E., Bristol-Myers Squibb Aktiebolag, Bristol-Myers Squibb Argentina S. R. L., Bristol-Myers Squibb Australia Pty. Ltd., Bristol-Myers Squibb Axia Limited, Bristol-Myers Squibb B.V., Bristol-Myers Squibb Belgium S.A., Bristol-Myers Squibb Business Services Limited, Bristol-Myers Squibb Canada Co., Bristol-Myers Squibb Canada International Limited, Bristol-Myers Squibb Delta Company Limited, Bristol-Myers Squibb Denmark Filial of Bristol-Myers Squibb AB, Bristol-Myers Squibb EMEA Sarl, Bristol-Myers Squibb Egypt LLC, Bristol-Myers Squibb Epsilon Holdings Unlimited Company, Bristol-Myers Squibb Farmaceutica Ltda., Bristol-Myers Squibb Farmaceutica Portuguesa S.A., Bristol-Myers Squibb GesmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Bristol-Myers Squibb Holding Germany GmbH & Co. KG, Bristol-Myers Squibb Holdings 2002 Limited, Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH, Bristol-Myers Squibb Holdings Ireland Unlimited Company, Bristol-Myers Squibb Holdings Limited, Bristol-Myers Squibb Holdings Pharma Ltd. Liability Company, Bristol-Myers Squibb Ilaclari Inc., Bristol-Myers Squibb India Pvt. Limited, Bristol-Myers Squibb International Company Unlimited Company, Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb Investco L.L.C., Bristol-Myers Squibb K.K., Bristol-Myers Squibb Kft., Bristol-Myers Squibb Luxembourg International S.C.A., Bristol-Myers Squibb Luxembourg S.a.r.l., Bristol-Myers Squibb MEA GmbH, Bristol-Myers Squibb Manufacturing Company, Bristol-Myers Squibb Marketing Services S.R.L., Bristol-Myers Squibb Middle East & Africa FZ-LLC, Bristol-Myers Squibb Norway Ltd., Bristol-Myers Squibb Nutricionales de Mexico S. de R.L. de C.V., Bristol-Myers Squibb Peru S.A., Bristol-Myers Squibb Pharma (HK) Ltd, Bristol-Myers Squibb Pharma (Thailand) Limited, Bristol-Myers Squibb Pharma Company, Bristol-Myers Squibb Pharma EEIG, Bristol-Myers Squibb Pharma Holding Company LLC, Bristol-Myers Squibb Pharma Ventures Corporation, Bristol-Myers Squibb Pharmaceuticals Limited, Bristol-Myers Squibb Pharmaceuticals Unlimited Company, Bristol-Myers Squibb Polska Sp. z o.o., Bristol-Myers Squibb Products SA, Bristol-Myers Squibb Puerto Rico Inc., Bristol-Myers Squibb Puerto Rico/Sanofi Pharmaceutical Partnership Puerto Rico, Bristol-Myers Squibb Romania S.R.L., Bristol-Myers Squibb S.A.U., Bristol-Myers Squibb S.r.l., Bristol-Myers Squibb SA, Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Bristol-Myers Squibb Sarl, Bristol-Myers Squibb Service Ltd., Bristol-Myers Squibb Services Sp. z o.o., Bristol-Myers Squibb Spol. s r.o., Bristol-Myers Squibb Theta Finance Ltd., Bristol-Myers Squibb Trustees Limited, Bristol-Myers Squibb Verwaltungs GmbH, Bristol-Myers Squibb de Colombia S.A., Bristol-Myers Squibb de Costa Rica Sociedad Anonima, Bristol-Myers Squibb de Guatemala S.A., Bristol-Myers Squibb de Mexico S. de R.L. de C.V., Bristol-Myers Squibb/Astrazeneca EEIG, Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Bristol-Myers de Venezuela S.C.A., CHT I LLC, CHT II LLC, CHT III LLC, CHT IV LLC, CR Finance Company LLC, Cardioxyl Pharmaceuticals, Cardioxyl Pharmaceuticals Inc., Celem LLC, Celem Ltd., Celgene, Celgene A.B., Celgene AS, Celgene Ab (Finland), Celgene Alpine Investment Co. II LLC, Celgene Alpine Investment Co. III LLC, Celgene Alpine Investment Co. LLC, Celgene ApS, Celgene B.V., Celgene BVBA, Celgene Brasil Produtos Farmacêuticos Ltda., Celgene CAR LLC, Celgene CAR Ltd., Celgene Chemicals Sarl, Celgene China Holdings LLC, Celgene Co., Celgene Corporation, Celgene Distribution B.V., Celgene EngMab GmbH, Celgene Europe B.V., Celgene Europe Limited, Celgene European Investment Company LLC, Celgene Financing Company LLC, Celgene Global Holdings Sarl, Celgene GmbH [Austria], Celgene GmbH [Germany], Celgene GmbH [Switzerland], Celgene Holdings East Corporation, Celgene Holdings II Sarl, Celgene Holdings III Sarl, Celgene Ilaç Pazarlama ve Ticaret Limited Şirketi, Celgene Inc., Celgene International Holdings Corporation, Celgene International II Sàrl, Celgene International III Sàrl, Celgene International Inc., Celgene International Sàrl, Celgene K.K., Celgene Kft., Celgene Limited [Hong Kong], Celgene Limited [Ireland], Celgene Limited [New Zealand], Celgene Limited [Taiwan], Celgene Limited [UK], Celgene Logistics Sàrl, Celgene Ltd, Celgene Luxembourg Sarl, Celgene Management Sàrl, Celgene NJ Investment Co, Celgene Netherlands B.V., Celgene Netherlands Investment B.V., Celgene Pharmaceutical (Shanghai) Co. Ltd., Celgene Pte. Ltd., Celgene Pty Ltd, Celgene Puerto Rico Distribution LLC, Celgene Quanticel Research Inc, Celgene R&D Sàrl, Celgene RIVOT LLC, Celgene RIVOT Ltd., Celgene RIVOT SRL, Celgene Receptos Limited, Celgene Receptos Sàrl, Celgene Research Incubator At Summit West LLC, Celgene Research S.L.U., Celgene Research and Development Company LLC, Celgene Research and Development I ULC, Celgene Research and Development II LLC, Celgene Research and Investment Company II LLC, Celgene S. de R.L. de C.V., Celgene S.L.U., Celgene S.R.L., Celgene SAS, Celgene Sarl AU, Celgene Sdn Bhd, Celgene Services Sàrl, Celgene Sociedade Unipessoal Lda, Celgene Sp. Z.o.o., Celgene Sro [Czech Republic], Celgene Summit Investment Co, Celgene Switzerland Holding Sarl, Celgene Switzerland II LLC, Celgene Switzerland Investment Sarl, Celgene Switzerland LLC, Celgene Switzerland Sarl, Celgene Tri A Holdings Ltd., Celgene Tri Sarl, Celgene UK Distribution Limited, Celgene UK Holdings Limited, Celgene UK Manufacturing II Limited, Celgene UK Manufacturing III Limited, Celgene UK Manufacturing Limited, Celgene d.o.o., Celgene sro [Slovakia], Celmed LLC, Celmed Ltd., ConvaTec Divestiture, Cormorant Pharmaceuticals, Cormorant Pharmaceuticals AB, Crosp Ltd., Delinia Inc., Deuteria Pharmaceuticals Inc., DuPont Pharmaceuticals, E. R. Squibb & Sons Inter-American Corporation, E. R. Squibb & Sons L.L.C., E. R. Squibb & Sons Limited, EWI Corporation, EngMab Sarl, F-star Alpha, FermaVir Pharmaceuticals L.L.C., FermaVir Research L.L.C., Flexus Biosciences, Flexus Biosciences Inc., Forbius, Galecto Biotech, GenPharm International L.L.C., Gloucester Pharmaceuticals LLC, Grove Insurance Company Ltd., Heyden Farmaceutica Portuguesa Limitada, IFM Therapeutics, Impact Biomedicines Inc., Inhibitex, Inhibitex L.L.C., Innate Tumor Immunity Inc., JuMP Holdings LLC, Juno Therapeutics GmbH, Juno Therapeutics Inc., Kosan Biosciences, Kosan Biosciences Incorporated, Linson Investments Limited, Mead Johnson (Manufacturing) Jamaica Limited, Mead Johnson Jamaica Ltd., Medarex, Morris Avenue Investment II LLC, Morris Avenue Investment LLC, MyoKardia, O.o.o. Bristol-Myers Squibb, Oy Bristol-Myers Squibb (Finland) AB, Padlock Therapeutics, Padlock Therapeutics Inc., Pharmion LLC, Princeton Pharmaceutical Products Inc., Receptos LLC, Receptos Services LLC, RedoxTherapies Inc., Route 22 Real Estate Holding Corporation, SPV A Holdings ULC, Seamair Insurance DAC, Signal Pharmaceuticals LLC, Sino-American Shanghai Squibb Pharmaceuticals Limited, Societe Francaise de Complements Alimentaires(S.O.F.C.A.), Squibb Middle East S.A., Summit West Celgene LLC, Swords Laboratories, VentiRx Pharmaceuticals Inc., Westwood-Intrafin SA, Westwood-Squibb Pharmaceuticals Inc., X-Body Inc., ZymoGenetics, ZymoGenetics Inc., ZymoGenetics LLC, ZymoGenetics Paymaster LLC, iPierian, and iPierian Inc..

When was Bristol-Myers Squibb founded?

Bristol-Myers Squibb was founded in 1887.

What is Bristol-Myers Squibb's official website?

The official website for Bristol-Myers Squibb is www.bms.com.

Where are Bristol-Myers Squibb's headquarters?

Bristol-Myers Squibb is headquartered at 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]

This page was last updated on 5/7/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Bristol-Myers Squibb Stock Forecast, Price & News

Adding

Adding

Adding Bristol-Myers Squibb

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links

Headlines

About Bristol-Myers Squibb

MarketRank™

Overall MarketRank™